ArticleFrontiers in neurology2025
Comparison of the presentation and electrophysiological characteristics of autoimmune nodopathies in patients with antibody-negative CIDP and CMT1.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Autoimmune nodopathy (AN), as patients positive for IgG4 autoantibodies against NF155, NF186, CNTN1, or CASPR1, is a distinct form of chronic inflammatory demyelinating polyneuropathy (CIDP) that shares similar clinical and electrophysiological characteristics with Charcot-Marie-Tooth disease type 1 (CMT1). This study aimed to determine the clinical presentation and electrophysiological features of AN and compare them with antibody-negative CIDP and CMT1. Methods: We collected clinical data from 29 patients who met the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) electrophysiological diagnostic criteria for definite CIDP. Autoimmune antibodies (anti-NF155, NF186, CNTN1, and CASPR1) were tested using cell-based assays. Additionally, 17 CMT1 patients, diagnosed with hereditary motor sensory neuropathy type 1, were included. We compared the clinical and electrophysiological characteristics of AN, antibody-negative CIDP, and CMT1 patients. Results: Among the 29 CIDP patients, 10 tested positive for autoantibodies (8 for NF155, 1 for CASPR1, and 1 for CNTN1). AN patients had a younger age of onset compared to antibody-negative CIDP and were similar in age to CMT1 patients. Hand tremor was more common in AN patients (60%) compared to antibody-negative CIDP (21%) and CMT1 (5.8%). Conversely, 76.4% of CMT1 patients exhibited cavus foot, significantly higher than the 20% in AN patients. Cerebrospinal fluid (CSF) analysis revealed higher cell count and protein levels in AN patients compared to antibody-negative CIDP and CMT1. AN patients showed poor response to corticosteroids and intravenous immunoglobulin (IVIG), but rituximab was more effective. Electrophysiological findings revealed significantly prolonged distal motor latencies (DML) in the tibial posterior and peroneal nerves, as well as prolonged F-wave latencies in the ulnar and posterior tibial nerves in AN patients than antibody-negative CIDP. In contrast, compared with AN, CMT1 patients showed prolonged DML and significantly reduced motor conduction velocities (MCV) in the median and ulnar nerves. AN patients exhibited sparing of the sural nerve, whereas this phenomenon was not observed in CMT1 patients. Conclusion: In young male patients with hand tremors, demyelinating electrophysiological features (especially prolonged DML and F-wave latencies), elevated CSF protein levels, and poor response to corticosteroids, autoimmune nodopathy, AN antibody testing is recommended. Compared to AN, CMT1 patients tend to have a slower disease course, less frequent tremors, and normal CSF protein levels. A median nerve DML greater than 10 ms and MCV less than 25 m/s supports a diagnosis of CMT1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.